Akinci, IH, Tarter, RE, Kirisci, L (2001). Concordance between verbal report and urine screen of recent marijuana use in adolescents. Addictive Behaviors
Albrecht, DS, Skosnik, PD, Vollmer, JM, Brumbaugh, MS, Perry, KM, Mock, BH, Zheng, QH, Federici, LA, Patton, EA, Herring, CM, Yoder, KK (2013). Striatal D2/D3 receptor availability is inversely correlated with cannabis consumption in chronic marijuana users. Drug and Alcohol Dependence
American Psychiatric Association (2005). Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision (DSM-IV-TR). American Psychiatric Association: Washington, DC.
Barkus, E, Morrison, P, Vuletic, D, Dickson, J, Ell, P, Pilowsky, L, Brenneisen, R, Holt, D, Powell, J, Kapur, S, Murray, R (2011). Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study. Journal of Psychopharmacology
Barkus, EJ, Stirling, J, Hopkins, RS, Lewis, S (2006). Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology
Belue, RC, Howlett, AC, Westlake, TM, Hutchings, DE (1995). The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxicology and Teratology
Berridge, KC, Robinson, TE (1998). What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?
Brain Research Reviews
Bhattacharyya, S, Crippa, JA, Allen, P, Martin-Santos, R, Borgwardt, S, Fusar-Poli, P, Rubia, K, Kambeitz, J, O'Carroll, C, Seal, ML, Giampietro, V, Brammer, M, Zuardi, AW, Atakan, Z, McGuire, PK (2012). Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Archives of General Psychiatry
Bianconi, F, Bonomo, M, Marconi, A, Kolliakou, A, Stilo, SA, Iyegbe, C, Gurillo Muñoz, P, Homayoun, S, Mondelli, V, Luzi, S, Dazzan, P, Prata, D, La Cascia, C, O'Connor, J, David, A, Morgan, C, Murray, RM, Lynskey, M, Di Forti, M (2016). Differences in cannabis-related experiences between patients with a first episode of psychosis and controls. Psychological Medicine
Bloomfield, MAP, Morgan, CJA, Egerton, A, Kapur, S, Curran, HV, Howes, OD (2014
a). Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biological Psychiatry
Bloomfield, MAP, Morgan, CJA, Kapur, S, Curran, HV, Howes, OD (2014
b). The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study. Psychopharmacology
Boehme, R, Deserno, L, Gleich, T, Katthagen, T, Pankow, A, Behr, J, Buchert, R, Roiser, JP, Heinz, A, Schlagenhauf, F (2015). Aberrant salience is related to reduced reinforcement learning signals and elevated dopamine synthesis capacity in healthy adults. Journal of Neuroscience
Bossong, MG, van Berckel, BN, Boellaard, R, Zuurman, L, Schuit, RC, Windhorst, AD, van Gerven, JM, Ramsey, NF, Lammertsma, AA, Kahn, RS (2009). Δ9-Tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology
Breivogel, CS, Childers, SR (2000). Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. Journal of Pharmacology and Experimental Therapeutics
Cherek, DR, Lane, SD, Dougherty, DM (2002). Possible amotivational effects following marijuana smoking under laboratory conditions. Experimental and Clinical Psychopharmacology
Cumming, P, Léger, GC, Kuwabara, H, Gjedde, A (1993). Pharmacokinetics of plasma 6-[18F]fluoro-l-3,4-dihydroxyphenylalanine [18F]FDOPA in humans. Journal of Cerebral Blood Flow and Metabolism
Curran, V, Brignell, C, Fletcher, S, Middleton, P, Henry, J (2002). Cognitive and subjective dose–response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology
D'Souza, DC, Perry, E, MacDougall, L, Ammerman, Y, Cooper, T, Wu, Y-T, Braley, G, Gueorguieva, R, Krystal, JH (2004). The psychotomimetic effects of intravenous Δ-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology
Egerton, A, Demjaha, A, McGuire, P, Mehta, MA, Howes, OD (2010). The test–retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. NeuroImage
Felder, CC, Veluz, JS, Williams, HL, Briley, EM, Matsuda, LA (1992). Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Molecular Pharmacology
Fernandez-Ruiz, J, Hernandez, M, Ramos, JA (2010). Cannabinoid–dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neuroscience and Therapeutics
First, MB, Spitzer, RL, Gibbon, M, Williams, JBW (1996). Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). American Psychiatric Press: Washington, DC.
Foltin, RW, Fischman, MW, Brady, JV, Kelly, TH, Bernstein, DJ, Nellis, MJ (1989). Motivational effects of smoked marijuana: behavioral contingencies and high-probability recreational activities. Pharmacology, Biochemistry, and Behavior
Fontes, MA, Bolla, KI, Cunha, PJ, Almeida, PP, Jungerman, F, Laranjeira, RR, Bressan, RA, Lacerda, ALT (2011). Cannabis use before age 15 and subsequent executive functioning. British Journal of Psychiatry
Freeman, D, Dunn, G, Murray, RM, Evans, N, Lister, R, Antley, A, Slater, M, Godlewska, B, Cornish, R, Williams, J, Di Simplicio, M, Igoumenou, A, Brenneisen, R, Tunbridge, EM, Harrison, PJ, Harmer, CJ, Cowen, P, Morrison, PD (2014). How cannabis causes paranoia: using the intravenous administration of 9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophrenia Bulletin
French, ED (1997). Δ9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neuroscience Letters
Ginovart, N, Tournier, BB, Moulin-Sallanon, M, Steimer, T, Ibanez, V, Millet, P (2012). Chronic Δ9-tetrahydrocannabinol exposure induces a sensitization of dopamine D2/3 receptors in the mesoaccumbens and nigrostriatal systems. Neuropsychopharmacology
Govaerts, SJ, Hermans, E, Lambert, DM (2004). Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. European Journal of Pharmaceutical Sciences
Gunn, RN, Lammertsma, AA, Hume, SP, Cunningham, VJ (1997). Parametric imaging of ligand–receptor binding in PET using a simplified reference region model. NeuroImage
Guttman, M, Léger, G, Reches, A, Evans, A, Kuwabara, H, Cedarbaum, JM, Gjedde, A (1993). Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Movement Disorders
Hartvig, P, Aquilonius, SM, Tedroff, J, Reibring, L, Agren, H, Bjurling, P, Ulin, J, Långström, B (1991). Positron emission tomography of l-DOPA utilization in the brains of rhesus monkeys and human volunteers. Acta Radiologica Supplementum
Hartvig, P, Torstenson, R, Tedroff, J, Watanabe, Y, Fasth, KJ, Bjurling, P, Longstrom, B (1997). Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography. Journal of Neural Transmission
Hoshi, H, Kuwabara, H, Léger, G, Cumming, P, Guttman, M, Gjedde, A (1993). 6-[18F]fluoro-l-DOPA metabolism in living human brain: a comparison of six analytical methods. Journal of Cerebral Blood Flow and Metabolism
Howes, OD, Bose, SK, Turkheimer, F, Valli, I, Egerton, A, Valmaggia, LR, Murray, RM, McGuire, P (2011). Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. American Journal of Psychiatry
Howes, OD, Montgomery, AJ, Asselin, MC, Murray, RM, Valli, I, Tabraham, P, Bramon-Bosch, E, Valmaggia, L, Johns, L, Broome, M, McGuire, PK, Grasby, PM (2009). Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Archives of General Psychiatry
Jager, G, Ramsey, NF (2008). Long-term consequences of adolescent cannabis exposure on the development of cognition, brain structure and function: an overview of animal and human research. Current Drug Abuse Reviews
Kamien, JB, Bickel, WK, Higgins, ST, Hughes, JR (1994). The effects of Δ9-tetrahydrocannabinol on repeated acquisition and performance of response sequences and on self-reports in humans. Behavioural Pharmacology
Kapur, S (2003). Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry
Kelley, BG, Thayer, SA (2004). Δ9-Tetrahydrocannabinol antagonizes endocannabinoid modulation of synaptic transmission between hippocampal neurons in culture. Neuropharmacology
Kuepper, R, Ceccarini, J, Lataster, J, van Os, J, van Kroonenburgh, M, van Gerven, JM, Marcelis, M, van Laere, K, Henquet, C (2013). Δ-9-Tetrahydrocannabinol-induced dopamine release as a function of psychosis risk: 18F-fallypride positron emission tomography study. PLOS ONE
Lane, SD, Cherek, DR (2002). Marijuana effects on sensitivity to reinforcement in humans. Neuropsychopharmacology
Lane, SD, Cherek, DR, Pietras, CJ, Steinberg, JL (2005). Performance of heavy marijuana-smoking adolescents on a laboratory measure of motivation. Addictive Behaviors
Lane, SD, Cherek, DR, Pietras, CJ, Tcheremissine, OV (2004). Acute marijuana effects on response–reinforcer relations under multiple variable-interval schedules. Behavioural Pharmacology
Martinez, D, Slifstein, M, Broft, A, Mawlawi, O, Hwang, D-R, Huang, Y, Cooper, T, Kegeles, L, Zarahn, E, Abi-Dargham, A, Haber, SN, Laruelle, M (2003). Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. Journal of Cerebral Blood Flow and Metabolism
Mason, O, Wakerley, D (2012). The psychotomimetic nature of dreams: an experimental study. Schizophrenia Research and Treatment
Medina, KL, Hanson, KL, Schweinsburg, AD, Cohen-Zion, M, Nagel, BJ, Tapert, SF (2007). Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence. Journal of the International Neuropsychological Society
Melis, M, Muntoni, AL, Pistis, M (2012). Endocannabinoids and the processing of value-related signals. Frontiers in Pharmacology
Melis, M, Pistis, M (2012). Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. Philosophical Transactions of the Royal Society B: Biological Sciences
Mendelson, JH, Babor, TF, Kuehnle, JC, Rossi, AM, Bernstein, JG, Mello, NK, Greenberg, I (1976). Behavioral and biologic aspects of marijuana use. Annals of the New York Academy of Sciences
Morgan, CJA, Gardener, C, Schafer, G, Swan, S, Demarchi, C, Freeman, TP, Warrington, P, Rupasinghe, I, Ramoutar, A, Tan, N, Wingham, G, Lewis, S, Curran, HV (2012). Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychological Medicine
Murray, RM, Quigley, H, Quattrone, D, Englund, A, Di Forti, M (in press). Traditional marijuana, high potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry.
NIMH Genetics Initiative (1992). Manual for the Family Interview for Genetic Studies (FIGS). National Institute of Mental Health: Rockville, MD.
Paronis, CA, Nikas, SP, Shukla, VG, Makriyannis, A (2012). Δ9-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice. Behavioural Pharmacology
Patlak, CS, Blasberg, RG (1985). Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. Journal of Cerebral Blood Flow and Metabolism
Petitet, F, Jeantaud, B, Reibaud, M, Imperato, A, Dubroeucq, MC (1998). Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sciences
Phillips, LJ, Yung, AR, McGorry, PD (2000). Identification of young people at risk of psychosis: validation of personal assessment and crisis evaluation clinic intake criteria. Australian and New Zealand Journal of Psychiatry
Pope, HG, Gruber, AJ, Hudson, JI, Huestis, MA, Yurgelun-Todd, D (2001). Neuropsychological performance in long-term cannabis users. Archives of General Psychiatry
Roiser, JP, Howes, OD, Chaddock, CA, Joyce, EM, McGuire, P (2013). Neural and behavioral correlates of aberrant salience in individuals at risk for psychosis. Schizophrenia Bulletin
Roiser, JP, Stephan, KE, den Ouden, HEM, Barnes, TRE, Friston, KJ, Joyce, EM (2009). Do patients with schizophrenia exhibit aberrant salience?
Schmidt, K, Roisier, JP (2009). Assessing the construct validity of aberrant salience. Frontiers in Behavioral Neuroscience
Scholes, KE, Martin-Iverson, MT (2009). Cannabis use and neuropsychological performance in healthy individuals and patients with schizophrenia. Psychological Medicine
Shen, M, Thayer, SA (1999). Δ9-Tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Molecular Pharmacology
Sim, LJ, Hampson, RE, Deadwyler, SA, Childers, SR (1996). Effects of chronic treatment with Δ9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPγS autoradiography in rat brain. Journal of Neuroscience
Smith, K, Flatley, J (2012). Drug Misuse Declared: Findings from the 2010/11 British Crime Survey (England and Wales). Office of National Statistics, Home Office: London.
Sobell, LC, Brown, J, Leo, GI, Sobell, MB (1996). The reliability of the alcohol timeline followback when administered by telephone and by computer. Drug and Alcohol Dependence
Solowij, N, Michie, PT (2007). Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?
Journal of Psychiatry and Neuroscience
Solowij, N, Michie, PT, Fox, AM (1991). Effects of long-term cannabis use on selective attention: an event-related potential study. Pharmacology, Biochemistry, and Behavior
Stiglick, A, Kalant, H (1983). Behavioral effects of prolonged administration of Δ9-tetrahydrocannabinol in the rat. Psychopharmacology
Stokes, P, Mehta, M, Curran, H, Breen, G, Grasby, P (2009). Can recreational doses of THC produce significant dopamine release in the human striatum?
Studholme, C, Hill, DLG, Hawkes, DJ (1996). Automated 3-D registration of MR and CT images of the head. Medical Image Analysis
Turkheimer, FE, Brett, M, Visvikis, D, Cunningham, VJ (1999). Multiresolution analysis of emission tomography images in the wavelet domain. Journal of Cerebral Blood Flow and Metabolism
United Nations Office on Drugs and Crime (2010). World Drug Report. United Nations: New York.
Urban, NBL, Slifstein, M, Thompson, JL, Xu, XY, Girgis, RR, Raheja, S, Haney, M, Abi-Dargham, A (2012). Dopamine release in chronic cannabis users: a [11C]raclopride positron emission tomography study. Biological Psychiatry
van Hell, HH, Vink, M, Ossewaarde, L, Jager, G, Kahn, RS, Ramsey, NF (2010). Chronic effects of cannabis use on the human reward system: an fMRI study. European Neuropsychopharmacology
Volkow, ND, Wang, GJ, Telang, F
et al. (2014). Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proceedings of the National Academy of Sciences USA
Wachtel, SR, ElSohly, MA, Ross, SA, Ambre, J, de Wit, H (2002). Comparison of the subjective effects of Δ9-tetrahydrocannabinol and marijuana in humans. Psychopharmacology (Berlin)
Zink, CF, Pagnoni, G, Martin, ME, Dhamala, M, Berns, GS (2003). Human striatal response to salient nonrewarding stimuli. Journal of Neuroscience